Reports

Drug name	NICE TAs	Comments
Octaplas®		Alternative to Factor XI when it is unavailable
Octreotide (Sandostatin LAR®) injection		Amber - palliative care use only Red - Oncology, acromegaly
Octreotide injection#8.3		Amber - palliative care use only Red - Oncology, acromegaly
Ofatumumab	TA344 - Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia	For hospital use only
Ofatumumab (Kesimpta®)	TA699 - Ofatumumab for treating relapsing multiple sclerosis
Oily phenol
Olaparib (Lynparza®)	TA381 - Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy TA598 - Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy TA620 - Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer TA693 - Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer TA908 - Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy
Olaratumab	TA465 - Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma	For hospital use only
Omalizumab	TA339 - Omalizumab for previously treated chronic spontaneous urticaria TA278 - Omalizumab for treating severe persistent allergic asthma	Hospital only
Omalizumab#13.5	TA339 - Omalizumab for previously treated chronic spontaneous urticaria

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports